KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Common Equity: 2009-2024

Historic Common Equity for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $778.3 million.

  • Pacira BioSciences' Common Equity fell 2.98% to $727.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.2 million, marking a year-over-year decrease of 2.98%. This contributed to the annual value of $778.3 million for FY2024, which is 10.55% down from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Common Equity is $778.3 million, which was down 10.55% from $870.1 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Common Equity registered a high of $870.1 million during FY2023, and its lowest value of $619.7 million during FY2020.
  • Its 3-year average for Common Equity is $807.8 million, with a median of $778.3 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first spiked by 74.59% in 2020, then dropped by 10.55% in 2024.
  • Pacira BioSciences' Common Equity (Yearly) stood at $619.7 million in 2020, then grew by 17.87% to $730.4 million in 2021, then grew by 6.11% to $775.0 million in 2022, then increased by 12.27% to $870.1 million in 2023, then decreased by 10.55% to $778.3 million in 2024.